Advances in Pediatric Pulmonary Arterial Hypertension

Overview

Journal Curr Opin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2012 Jan 26

PMID 22274573

Citations 13

Authors

Dunbar Ivy

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Pulmonary arterial hypertension (PAH) is an important cause of morbidity and mortality in children. Approved medications for the treatment of adult PAH have been used to treat children, but evidence-based treatment algorithms for children are lacking.

Recent Findings: Pediatric PAH registries have begun to define the incidence and prevalence of idiopathic PAH and PAH associated with congenital heart disease. A pediatric-specific classification of pulmonary hypertensive vascular disease has been proposed. Furthermore, the first randomized placebo-controlled trial of type-5 phosphodiesterase therapy in treatment-naïve children with PAH has been completed and reported. This trial highlights the importance of the difficulties of performing clinical trials in children with targeted PAH therapy as well as the importance of long-term follow-up of adverse events.

Summary: Classification, clinical trials, and therapy for children with PAH must take into account the unique aspects of PAH in children.

Citing Articles

Right ventricular-vascular coupling ratio in pediatric pulmonary arterial hypertension: A comparison between cardiac magnetic resonance and right heart catheterization measurements.

Breeman K, Dufva M, Ploegstra M, Kheyfets V, Willems T, Wigger J Int J Cardiol. 2019; 293:211-217.

PMID: 31109778 PMC: 6710117. DOI: 10.1016/j.ijcard.2019.05.021.

The Role of Biomarkers and Surrogate End Points in Drug Development for Neonatal Pulmonary Arterial Hypertension.

Sun H, Stockbridge N, Ariagno R, Murphy D Neoreviews. 2017; 17(2):e87-e92.

PMID: 28943808 PMC: 5609821. DOI: 10.1542/neo.17-2-e87.

Pulmonary Hypertension in Children - a Practical Approach.

Cinteza E, Nicolescu A, Filip C, Lupu A, Nicolae G, Duica G Maedica (Bucur). 2017; 10(3):237-242.

PMID: 28261360 PMC: 5327836.

Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Kim J, McSweeney J, Lee J, Ivy D Pediatr Crit Care Med. 2016; 17(3 Suppl 1):S89-100.

PMID: 26945333 PMC: 4820013. DOI: 10.1097/PCC.0000000000000622.

Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009.

Frank D, Crystal M, Morales D, Gerald K, Hanna B, Mallory Jr G Pulm Circ. 2015; 5(2):339-48.

PMID: 26064460 PMC: 4449246. DOI: 10.1086/681226.

References

Yeager M, Nguyen C, Belchenko D, Colvin K, Takatsuki S, Ivy D . Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J. 2011; 39(1):104-11. PMC: 3319160. DOI: 10.1183/09031936.00072311. View

Ivy D, Rosenzweig E, Lemarie J, Brand M, Rosenberg D, Barst R . Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010; 106(9):1332-8. PMC: 2966874. DOI: 10.1016/j.amjcard.2010.06.064. View

Namachivayam P, Theilen U, Butt W, Cooper S, Penny D, Shekerdemian L . Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006; 174(9):1042-7. DOI: 10.1164/rccm.200605-694OC. View

Carmosino M, Friesen R, Doran A, Ivy D . Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg. 2007; 104(3):521-7. PMC: 1934984. DOI: 10.1213/01.ane.0000255732.16057.1c. View

Ghofrani H, Hoeper M, Halank M, Meyer F, Staehler G, Behr J . Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010; 36(4):792-9. DOI: 10.1183/09031936.00182909. View

Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12):896-903. DOI: 10.1056/NEJMoa012212. View

Zhao Y, Courtman D, Deng Y, Kugathasan L, Zhang Q, Stewart D . Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005; 96(4):442-50. DOI: 10.1161/01.RES.0000157672.70560.7b. View

Galie N, Brundage B, Ghofrani H, Oudiz R, Simonneau G, Safdar Z . Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119(22):2894-903. DOI: 10.1161/CIRCULATIONAHA.108.839274. View

Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D . First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009; 33(4):785-92. DOI: 10.1183/09031936.00039808. View

10.

Karatza A, Bush A, Magee A . Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005; 100(2):267-73. DOI: 10.1016/j.ijcard.2004.09.002. View

11.

Tissot C, Beghetti M . Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag. 2009; 5(1):325-31. PMC: 2672461. DOI: 10.2147/vhrm.s3222. View

12.

Atz A, Adatia I, Lock J, Wessel D . Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol. 1999; 33(3):813-9. DOI: 10.1016/s0735-1097(98)00668-8. View

13.

Atz A, Lefler A, Fairbrother D, Uber W, Bradley S . Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002; 124(3):628-9. DOI: 10.1067/mtc.2002.125265. View

14.

Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

15.

Yung D, Widlitz A, Rosenzweig E, Kerstein D, Maislin G, Barst R . Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004; 110(6):660-5. DOI: 10.1161/01.CIR.0000138104.83366.E9. View

16.

Lammers A, Adatia I, Del Cerro M, Diaz G, Freudenthal A, Freudenthal F . Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ. 2011; 1(2):280-285. PMC: 3161406. DOI: 10.4103/2045-8932.83445. View

17.

Steinhorn R, Kinsella J, Pierce C, Butrous G, Dilleen M, Oakes M . Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009; 155(6):841-847.e1. DOI: 10.1016/j.jpeds.2009.06.012. View

18.

Friesen R, Williams G . Anesthetic management of children with pulmonary arterial hypertension. Paediatr Anaesth. 2008; 18(3):208-16. DOI: 10.1111/j.1460-9592.2008.02419.x. View

19.

Del Cerro M, Abman S, Diaz G, Freudenthal A, Freudenthal F, Harikrishnan S . A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011; 1(2):286-298. PMC: 3161725. DOI: 10.4103/2045-8932.83456. View

20.

Maiya S, Hislop A, Flynn Y, Haworth S . Response to bosentan in children with pulmonary hypertension. Heart. 2005; 92(5):664-70. PMC: 1860919. DOI: 10.1136/hrt.2005.072314. View